Navigating Treatment Burden and Family Priorities in PLGG

In this episode, Dr. Chi and Dr. Abdelbaki discuss how disease and treatment burden shape decision-making in pediatric low-grade glioma (PLGG), and how clinicians guide families through a long and individualized treatment course.

With 50%–60% of tumors unresectable and even completely resected tumors sometimes leaving children with seizures, headaches, or effects on vision and endocrine function, the disease burden extends well beyond imaging. Management may span 4, 7, or even 10 years of therapy, making PLGG "a long marathon, definitely not a sprint.” Strategic sequencing is essential, with a generally conservative approach favoring upfront chemotherapy plus or minus an oral combination depending on BRAF V600E mutation status. For younger children, the challenge of administering daily or twice-daily oral medications is a practical barrier. Long-term concerns, such as growth, vision, and unknown effects on fertility, weigh heavily and family preferences vary: Some prioritize published evidence, while others favor less frequent dosing and fewer clinic visits.

Treatment decisions are rarely straightforward, and families should be cautioned against comparing their child's plan to others on social media. Children with the same tumor name may receive different therapies based on age, tumor biology, rate of visual decline, geography, and ability to swallow capsules. The pediatric neuro-oncology community is small and collaborative, with second opinions welcomed and individualized care as the guiding principle.

In the next episode, "Observation vs. Treatment in PLGG: Functional Outcomes, NF1 Status, and Shared Decision-Making," the panel examines when observation may be appropriate, how NF1 status influences the treatment threshold, and how clinicians navigate shared decision-making with families.